Migraine Headache: Practice Essentials, Background, Pathophysiology

  • Headache Classification Committee of the International Headache Society. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan. 38 (1):1-211. [Medline].

  • Hughes S. Choosing Wisely: 5 Headache Interventions Discouraged. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/814816. Accessed: November 25, 2013.

  • Loder E, Weizenbaum E, Frishberg B, Silberstein S; the American Headache Society Choosing Wisely Task Force. Choosing Wisely in Headache Medicine: The American Headache Society’s List of Five Things Physicians and Patients Should Question. Headache. Available at http://onlinelibrary.wiley.com/doi/10.1111/head.12233/abstract. Accessed: November 25, 2013.

  • [Guideline] Matchar DB, Young WB, Rosenberg JA, et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. American Academy of Neurology. Accessed February 10, 2011. [Full Text].

  • Silberstein SD, Freitag FG. Preventative treatment of migraine. Neurology. 2003. 60(7):S38-44.

  • Anderson P. New Screening Tool for Chronic Migraine. Medscape Medical News. Available at http://www.medscape.com/viewarticle/831261. Accessed: September 8, 2014.

  • Anderson P. New Headache Classification System Published. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/807334. Accessed: July 15, 2013.

  • [Guideline] Solomon GD, Cady RK, Klapper JA, Ryan RE Jr. Standards of care for treating headache in primary care practice. National Headache Foundation. Cleve Clin J Med. 1997 Jul-Aug. 64(7):373-83. [Medline].

  • [Guideline] Ducharme J. Canadian Association of Emergency Physicians Guidelines for the acute management of migraine headache. J Emerg Med. 1999 Jan-Feb. 17(1):137-44. [Medline].

  • Perciaccante A. Migraine is characterized by a cardiac autonomic dysfunction. Headache. 2008 Jun. 48(6):973. [Medline].

  • May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999 Feb. 19(2):115-27. [Medline].

  • Cutrer FM, Charles A. The neurogenic basis of migraine. Headache. 2008 Oct. 48(9):1411-4. [Medline].

  • Waeber C, Moskowitz MA. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology. 2003 Oct 28. 61(8 Suppl 4):S9-20. [Medline].

  • Welch KM. Contemporary concepts of migraine pathogenesis. Neurology. 2003 Oct 28. 61(8 Suppl 4):S2-8. [Medline].

  • Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol. 2009 Aug. 8(8):718-23. [Medline].

  • Moulton EA, Burstein R, Tully S, Hargreaves R, Becerra L, Borsook D. Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS One. 2008. 3(11):e3799. [Medline]. [Full Text].

  • Richter F, Lehmenkühler A. [Cortical spreading depression (CSD): a neurophysiological correlate of migraine aura]. Schmerz. 2008 Oct. 22(5):544-6, 548-50. [Medline].

  • Martins-Oliveira A, Speciali JG, Dach F, Marcaccini AM, Gonçalves FM, Gerlach RF, et al. Different circulating metalloproteinases profiles in women with migraine with and without aura. Clin Chim Acta. 2009 Oct. 408(1-2):60-4. [Medline].

  • Imamura K, Takeshima T, Fusayasu E, Nakashima K. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache. 2008 Jan. 48(1):135-9. [Medline].

  • Piilgaard H, Lauritzen M. Persistent increase in oxygen consumption and impaired neurovascular coupling after spreading depression in rat neocortex. J Cereb Blood Flow Metab. 2009 Sep. 29(9):1517-27. [Medline].

  • Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000 May. 47(5):614-24. [Medline].

  • Peroutka SJ. Dopamine and migraine. Neurology. 1997 Sep. 49(3):650-6. [Medline].

  • Sun-Edelstein C, Mauskop A. Role of magnesium in the pathogenesis and treatment of migraine. Expert Rev Neurother. 2009 Mar. 9(3):369-79. [Medline].

  • Napoli R, Guardasole V, Zarra E, Matarazzo M, D’Anna C, Saccà F, et al. Vascular smooth muscle cell dysfunction in patients with migraine. Neurology. 2009 Jun 16. 72(24):2111-4. [Medline].

  • Gruber HJ, Bernecker C, Lechner A, Weiss S, Wallner-Blazek M, Meinitzer A, et al. Increased nitric oxide stress is associated with migraine. Cephalalgia. 2010 Apr. 30(4):486-92. [Medline].

  • Tietjen GE, Herial NA, White L, Utley C, Kosmyna JM, Khuder SA. Migraine and biomarkers of endothelial activation in young women. Stroke. 2009 Sep. 40(9):2977-82. [Medline].

  • Hamed SA. The vascular risk associations with migraine: relation to migraine susceptibility and progression. Atherosclerosis. 2009 Jul. 205(1):15-22. [Medline].

  • Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008 Nov 25. 71(22):1821-8. [Medline].

  • Kors EE, Haan J, Ferrari MD. Genetics of primary headaches. Curr Opin Neurol. 1999 Jun. 12(3):249-54. [Medline].

  • Barbas NR, Schuyler EA. Heredity, genes, and headache. Semin Neurol. 2006 Nov. 26(5):507-14. [Medline].

  • Chasman DI, Schürks M, Anttila V, de Vries B, Schminke U, Launer LJ, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet. 2011 Jun 12. 43(7):695-8. [Medline]. [Full Text].

  • Anttila V, Stefansson H, Kallela M, Todt U, Terwindt GM, Calafato MS, et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet. 2010 Oct. 42(10):869-73. [Medline]. [Full Text].

  • Ligthart L, de Vries B, Smith AV, Ikram MA, Amin N, Hottenga JJ, et al. Meta-analysis of genome-wide association for migraine in six population-based European cohorts. Eur J Hum Genet. 2011 Aug. 19(8):901-7. [Medline]. [Full Text].

  • Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996 Nov 1. 87(3):543-52. [Medline].

  • Thomsen LL, Kirchmann M, Bjornsson A, Stefansson H, Jensen RM, Fasquel AC, et al. The genetic spectrum of a population-based sample of familial hemiplegic migraine. Brain. 2007 Feb. 130:346-56. [Medline].

  • Ferrari MD. Heritability of migraine. Neurology. 2003. 60(7):S15-20.

  • De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003 Feb. 33(2):192-6. [Medline].

  • Kahlig KM, Rhodes TH, Pusch M, Freilinger T, Pereira-Monteiro JM, Ferrari MD, et al. Divergent sodium channel defects in familial hemiplegic migraine. Proc Natl Acad Sci U S A. 2008 Jul 15. 105(28):9799-804. [Medline]. [Full Text].

  • Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005 Jul 30-Aug 5. 366(9483):371-7. [Medline].

  • Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain. 2004 Nov. 127:2533-9. [Medline].

  • Richards A, van den Maagdenberg AM, Jen JC, Kavanagh D, Bertram P, Spitzer D, et al. C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet. 2007 Sep. 39(9):1068-70. [Medline].

  • Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K, Massin P, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med. 2006 Apr 6. 354(14):1489-96. [Medline].

  • Stam AH, Haan J, van den Maagdenberg AM, Ferrari MD, Terwindt GM. Migraine and genetic and acquired vasculopathies. Cephalalgia. 2009 Sep. 29(9):1006-17. [Medline].

  • MacGregor EA. Menstrual migraine. Curr Opin Neurol. 2008 Jun. 21(3):309-15. [Medline].

  • Allais G, Gabellari IC, De Lorenzo C, Mana O, Benedetto C. Oral contraceptives in migraine. Expert Rev Neurother. 2009 Mar. 9(3):381-93. [Medline].

  • Wöber C, Brannath W, Schmidt K, Kapitan M, Rudel E, Wessely P, et al. Prospective analysis of factors related to migraine attacks: the PAMINA study. Cephalalgia. 2007 Apr. 27(4):304-14. [Medline].

  • Klein E, Spencer D. Migraine frequency and risk of cardiovascular disease in women. Neurology. 2009 Aug 25. 73(8):e42-3. [Medline].

  • Woodward M. Migraine and the risk of coronary heart disease and ischemic stroke in women. Womens Health (Lond Engl). 2009 Jan. 5(1):69-77. [Medline].

  • Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ. 2009 Mar 10. 338:b664. [Medline]. [Full Text].

  • Anderson, P. Migraine Tied to Hypertension Risk in Women. Medscape Medical News. Available at http://www.medscape.com/viewarticle/879249. April 28, 2017; Accessed: May 9, 2017.

  • Scher AI, Gudmundsson LS, Sigurdsson S, Ghambaryan A, Aspelund T, Eiriksdottir G, et al. Migraine headache in middle age and late-life brain infarcts. JAMA. 2009 Jun 24. 301(24):2563-70. [Medline].

  • Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016 May 31. 353:i2610. [Medline].

  • Kruit MC, Launer LJ, Overbosch J, van Buchem MA, Ferrari MD. Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. Cephalalgia. 2009 Mar. 29(3):351-9. [Medline].

  • Welch KM. Iron in the migraine brain; a resilient hypothesis. Cephalalgia. 2009 Mar. 29(3):283-5. [Medline].

  • Nguyen RH, Ford S, Calhoun AH, Holden JK, Gracely RH, Tommerdahl M. Neurosensory assessments of migraine. Brain Res. 2013 Jan 5. [Medline].

  • Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002 Mar 26. 58(6):885-94. [Medline].

  • Stewart WF, Linet MS, Celentano DD, Van Natta M, Ziegler D. Age- and sex-specific incidence rates of migraine with and without visual aura. Am J Epidemiol. 1991 Nov 15. 134(10):1111-20. [Medline].

  • Hsu LC, Wang SJ, Fuh JL. Prevalence and impact of migrainous vertigo in mid-life women: a community-based study. Cephalalgia. 2011 Jan. 31(1):77-83. [Medline].

  • Burton WN, Landy SH, Downs KE, Runken MC. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc. 2009 May. 84(5):436-45. [Medline]. [Full Text].

  • Bille B. Migraine in childhood and its prognosis. Cephalalgia. 1981 Jun. 1(2):71-5. [Medline].

  • Milhaud D, Bogousslavsky J, van Melle G, Liot P. Ischemic stroke and active migraine. Neurology. 2001 Nov 27. 57(10):1805-11. [Medline].

  • Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain. 2005 Sep. 128:2068-77. [Medline].

  • Bigal ME, Kurth T, Hu H, Santanello N, Lipton RB. Migraine and cardiovascular disease: possible mechanisms of interaction. Neurology. 2009 May 26. 72(21):1864-71. [Medline]. [Full Text].

  • Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari MD, Launer LJ. Cardiovascular risk factors and migraine: the GEM population-based study. Neurology. 2005 Feb 22. 64(4):614-20. [Medline].

  • Kurth T, Schürks M, Logroscino G, Buring JE. Migraine frequency and risk of cardiovascular disease in women. Neurology. 2009 Aug 25. 73(8):581-8. [Medline]. [Full Text].

  • Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, et al. Migraine and cardiovascular disease: a population-based study. Neurology. 2010 Feb 23. 74(8):628-35. [Medline].

  • Gudmundsson LS, Scher AI, Aspelund T, Eliasson JH, Johannsson M, Thorgeirsson G, et al. Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study. BMJ. 2010 Aug 24. 341:c3966. [Medline]. [Full Text].

  • International Headache Society. IHS Classification ICHD-II: Migraine. Available at http://ihs-classification.org/en/02_klassifikation/02_teil1/01.00.00_migraine.html. Accessed: March 27, 2013.

  • Le H, Tfelt-Hansen P, Russell MB, Skytthe A, Kyvik KO, Olesen J. Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia. 2011 Jan. 31(1):43-64. [Medline].

  • Martin VT, Fanning KM, Serrano D, Buse DC, Reed ML, Lipton RB. Asthma is a risk factor for new onset chronic migraine: Results from the American migraine prevalence and prevention study. Headache. 2015 Nov 19. [Medline].

  • Loder E. Migraine with aura and increased risk of ischaemic stroke. BMJ. 2009 Oct 27. 339:b4380. [Medline].

  • Kurth T, Kase CS, Schürks M, Tzourio C, Buring JE. Migraine and risk of haemorrhagic stroke in women: prospective cohort study. BMJ. 2010 Aug 24. 341:c3659. [Medline]. [Full Text].

  • Harling DW, Peatfield RC, Van Hille PT, Abbott RJ. Thunderclap headache: is it migraine?. Cephalalgia. 1989 Jun. 9(2):87-90. [Medline].

  • Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology. 1993 Sep. 43(9):1678-83. [Medline].

  • Anderson P. Neuropeptide May Be Biomarker for Chronic Migraine. Medscape Medical News. Aug 27 2013. [Full Text].

  • Cernuda-Morollón E, Larrosa D, Ramón C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013 Aug 23. [Medline].

  • Silberstein SD, Edvinsson L. Is CGRP a marker for chronic migraine?. Neurology. 2013 Aug 28. [Medline].

  • Wilper A, Woolhandler S, Himmelstein D, Nardin R. Impact of insurance status on migraine care in the United States: a population-based study. Neurology. 2010 Apr 13. 74(15):1178-83. [Medline].

  • Detsky ME, McDonald DR, Baerlocher MO, Tomlinson GA, McCrory DC, Booth CM. Does this patient with headache have a migraine or need neuroimaging?. JAMA. 2006 Sep 13. 296(10):1274-83. [Medline].

  • Sahai-Srivastava S, Desai P, Zheng L. Analysis of headache management in a busy emergency room in the United States. Headache. 2008 Jun. 48(6):931-8. [Medline].

  • Tornabene SV, Deutsch R, Davis DP, Chan TC, Vilke GM. Evaluating the use and timing of opioids for the treatment of migraine headaches in the emergency department. J Emerg Med. 2009 May. 36(4):333-7. [Medline].

  • Friedman BW, Solorzano C, Esses D, Xia S, Hochberg M, Dua N, et al. Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. Ann Emerg Med. 2010 Jul. 56(1):7-17. [Medline]. [Full Text].

  • Kelman L. Women’s issues of migraine in tertiary care. Headache. 2004 Jan. 44(1):2-7. [Medline].

  • US Food and Drug Administration. FDA allows marketing of first device to relieve migraine headache pain [press release]. December 13, 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm378608.htm. Accessed: December 23, 2013.

  • Jeffrey S. FDA approves first device to treat migraine pain. Medscape Medical News. December 13, 2013. [Full Text].

  • Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010 Apr. 9(4):373-80. [Medline].

  • eNeura Therapeutics. Clinical trials — study: migraine with aura. Available at http://www.eneura.com/clinical_trials.html. Accessed: January 28, 2014.

  • Holroyd KA, Cottrell CK, O’Donnell FJ, Cordingley GE, Drew JB, Carlson BW, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ. 2010 Sep 29. 341:c4871. [Medline]. [Full Text].

  • Brauser, D. FDA Clears Vagus Nerve Stimulator for Migraine Pain. Medscape Medical News. Available at https://www.medscape.com/viewarticle/891930. January 29, 2018; Accessed: January 30, 2018.

  • Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, et al. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Headache. 2019 May 9. [Medline].

  • Derry S, Moore RA, McQuay HJ. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010 Nov 10. CD008040. [Medline].

  • Matchar DB. Acute management of migraine: highlights of the US Headache Consortium. Neurology. 60(7):S21-3.

  • Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg Med. 2011 May. 57(5):475-482.e1. [Medline].

  • Taggart E, Doran S, Kokotillo A, Campbell S, Villa-Roel C, Rowe BH. Ketorolac in the treatment of acute migraine: a systematic review. Headache. 2013 Feb. 53(2):277-87. [Medline].

  • [Guideline] American Academy of Neurology. Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1995 Mar. 45(3 Pt 1):585-7. [Medline].

  • Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int J Clin Pract. 2006 Jun. 60(6):698-706. [Medline].

  • Barclay L. FDA Approves Transdermal Patch for Migraine. Available at http://www.medscape.com/viewarticle/777871. Accessed: January 29, 2013.

  • Cady RK, McAllister PJ, Spierings EL, Messina J, Carothers J, Djupesland PG, et al. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study). Headache. 2015 Jan. 55 (1):88-100. [Medline].

  • Anderson, P. FDA Okays Onzetra Xsail Intranasal Migraine Medication. Medscape Medical News. Available at http://www.medscape.com/viewarticle/857970. January 29, 2016; Accessed: February 3, 2016.

  • Brandes JL, Kudrow D, Stark SR, O’Carroll CP, Adelman JU, O’Donnell FJ, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007 Apr 4. 297(13):1443-54. [Medline].

  • Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018 Dec 11. 91 (24):e2222-e2232. [Medline]. [Full Text].

  • Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019 Jul 1. 142 (7):1894-1904. [Medline]. [Full Text].

  • Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, et al. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019 Oct. 39 (11):1343-1357. [Medline]. [Full Text].

  • Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, et al. Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019 Dec 5. 381 (23):2230-2241. [Medline].

  • Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019 Nov 19. 322 (19):1887-1898. [Medline].

  • Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, et al. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019 Jul 11. 381 (2):142-149. [Medline]. [Full Text].

  • Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31. 394 (10200):737-745. [Medline].

  • Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med. 2010 Jul. 56(1):1-6. [Medline].

  • Belotti EA, Taddeo I, Ragazzi M, Pifferini R, Simonetti GD, Bianchetti MG, et al. Chronic impact of topiramate on acid-base balance and potassium in childhood. Eur J Paediatr Neurol. 2010 Sep. 14(5):445-8. [Medline].

  • Misra UK, Kalita J, Bhoi SK. Allodynia in Migraine: Clinical Observation and Role of Prophylactic Therapy. Clin J Pain. 2013 Jan 16. [Medline].

  • [Guideline] Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24. 78(17):1346-53. [Medline]. [Full Text].

  • Krymchantowski AV, Jevoux C, Moreira PF. An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine. Pain Med. 2010 Jan. 11(1):48-52. [Medline].

  • Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004 Feb 25. 291(8):965-73. [Medline].

  • Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001 Feb. 41(2):119-28. [Medline].

  • Jeffrey S. FDA Okays First Drug for Migraine Prevention in Adolescents. Medscape Medical News. Mar 28 2014. [Full Text].

  • Topamax (topiramate) prescribing information [package insert]. Titusville, NJ.: Janssen Pharmaceuticals, Inc., Titusville, NJ. March 2014. 2014. Available at [Full Text].

  • Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003 Jan 1. 289(1):65-9. [Medline].

  • Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001 Jan 6. 322(7277):19-22. [Medline]. [Full Text].

  • Conway S, Delplanche C, Crowder J, Rothrock J. Botox therapy for refractory chronic migraine. Headache. 2005 Apr. 45(4):355-7. [Medline].

  • Schulte-Mattler WJ, Martinez-Castrillo JC. Botulinum toxin therapy of migraine and tension-type headache: comparing different botulinum toxin preparations. Eur J Neurol. 2006 Feb. 13 Suppl 1:51-4. [Medline].

  • Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 Jun. 50(6):921-36. [Medline].

  • [Guideline] Simpson David M., Hallett Mark, Ashman Eric J., et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. April 18, 2016. [Full Text].

  • Reuter U, Goadsby P, Lanteri-Minet M, Ferrari M, Wen S, Klatt J. Efficacy and safety of erenumab in episodic migraine patients with 2-4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study. Presented at the American Academy of Neurology 2018 Annual Meeting. Emerging Science Abstract 009. April 24, 2018. Los Angeles, CA.

  • Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018 May. 38 (6):1026-1037. [Medline].

  • Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017 Nov 30. 377 (22):2123-2132. [Medline].

  • Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017 Nov 30. 377 (22):2113-2122. [Medline]. [Full Text].

  • Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018 Sep 1. 75 (9):1080-1088. [Medline]. [Full Text].

  • Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018 Jul. 38 (8):1442-1454. [Medline].

  • Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020 Feb 19. 333102420905132. [Medline].

  • Vyepti (eptinezumab) [package insert]. Bothell, WA: Lundbeck Seattle Biopharmaceuticals, Inc. February 2020. Available at [Full Text].

  • Jeffrey S. FDA Approves First Device to Prevent Migraine. Medscape Medical News. Available at http://www.medscape.com/viewarticle/821810. Accessed: March 17, 2014.

  • Walling I, Panse D, Gee L, Maietta T, Kaszuba B, Kumar V, et al. The use of focused ultrasound for the treatment of cutaneous allodynia associated with chronic migraine. Brain Res. 2018 Aug 2. [Medline].

  • Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache. 2001 Nov-Dec. 41(10):976-80. [Medline].

  • Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology. 2010 Oct 26. 75(17):1527-32. [Medline].

  • De Leo V, Scolaro V, Musacchio MC, Di Sabatino A, Morgante G, Cianci A. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril. 2011 Oct. 96(4):917-20. [Medline].

  • von Peter S, Ting W, Scrivani S, Korkin E, Okvat H, Gross M, et al. Survey on the use of complementary and alternative medicine among patients with headache syndromes. Cephalalgia. 2002 Jun. 22(5):395-400. [Medline].

  • Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004 Dec 28. 63(12):2240-4. [Medline].

  • Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. 1998 Feb. 50(2):466-70. [Medline].

  • Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005 Feb 22. 64(4):713-5. [Medline].

  • Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia. 2011 Jun. 31(8):897-905. [Medline].

  • Ferrari MD, Odink J, Tapparelli C, Van Kempen GM, Pennings EJ, Bruyn GW. Serotonin metabolism in migraine. Neurology. 1989 Sep. 39(9):1239-42. [Medline].

  • Arnadottir TS, Sigurdardottir AK. Is craniosacral therapy effective for migraine? Tested with HIT-6 Questionnaire. Complement Ther Clin Pract. 2013 Feb. 19(1):11-4. [Medline].

  • John PJ, Sharma N, Sharma CM, Kankane A. Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial. Headache. 2007 May. 47(5):654-61. [Medline].

  • Linde K, Vickers A, Hondras M, ter Riet G, Thormählen J, Berman B, et al. Systematic reviews of complementary therapies – an annotated bibliography. Part 1: acupuncture. BMC Complement Altern Med. 2001. 1:3. [Medline]. [Full Text].

  • Walker JE. QEEG-guided neurofeedback for recurrent migraine headaches. Clin EEG Neurosci. 2011 Jan. 42(1):59-61. [Medline].

  • Nestoriuc Y, Martin A. Efficacy of biofeedback for migraine: a meta-analysis. Pain. 2007 Mar. 128(1-2):111-27. [Medline].

  • Rosenzweig S, Greeson JM, Reibel DK, Green JS, Jasser SA, Beasley D. Mindfulness-based stress reduction for chronic pain conditions: variation in treatment outcomes and role of home meditation practice. J Psychosom Res. 2010 Jan. 68(1):29-36. [Medline].

  • Dirnberger F, Becker K. Surgical treatment of migraine headaches by corrugator muscle resection. Plast Reconstr Surg. 2004 Sep 1. 114(3):652-7; discussion 658-9. [Medline].

  • Rockett FC, de Oliveira VR, Castro K, Chaves ML, Perla Ada S, Perry ID. Dietary aspects of migraine trigger factors. Nutr Rev. 2012 Jun. 70(6):337-56. [Medline].

  • Tepper SJ. Complementary and alternative treatments for childhood headaches. Curr Pain Headache Rep. 2008 Oct. 12(5):379-83. [Medline].

  • Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia. 2011 Oct. 31(14):1428-38. [Medline]. [Full Text].

  • Busch V, Gaul C. Exercise in migraine therapy–is there any evidence for efficacy? A critical review. Headache. 2008 Jun. 48(6):890-9. [Medline].

  • Durham PL, Garrett FG. Neurological mechanisms of migraine: potential of the gap-junction modulator tonabersat in prevention of migraine. Cephalalgia. 2009 Nov. 29 Suppl 2:1-6. [Medline].

  • Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P. Future drugs for migraine. Intern Emerg Med. 2009 Oct. 4(5):367-73. [Medline].

  • Dagenais R, Zed PJ. Intranasal lidocaine for acute management of primary headaches: a systematic review. Pharmacotherapy. 2018 Aug 11. [Medline].

  • [Guideline] Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24. 78 (17):1337-45. [Medline].

  • [Guideline] Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24. 78 (17):1346-53. [Medline].

  • Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, et al. Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2016 Jun. 56 (6):911-40. [Medline].

  • [Guideline] Silberstein S. The Management of Adults With Acute Migraine in the Emergency Department. Headache. 2016 Jun. 56 (6):907-8. [Medline].

  • American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019 Jan. 59 (1):1-18. [Medline].

  • Brauser D. AHS Releases Updated Guidance on Migraine Treatment. Medscape Medical News. Available at https://www.medscape.com/viewarticle/907493. 2019 Jan 10; Accessed: January 31, 2019.

  • [Guideline] The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004. 24 Suppl 1:9-160. [Medline].

  • Imitrex (sumatriptan succinate) injection. Prescribing Information. GlaxoSmithKline. February 2010. [Full Text].

  • Imitrex (sumatriptan succinate) tablets. Prescribing Information. GlaxoSmithKline. February 2010. [Full Text].

  • Imitrex (sumatriptan) Nasal Spray. Prescribing Information. GlaxoSmithKline. February 2010. [Full Text].

  • Leonardi M, Mathers C. Global burden of migraine in the Year 2000: summary of methods and data sources. World Health Organization. Available at http://www.who.int/healthinfo/statistics/bod_migraine.pdf. Accessed: March 27, 2013.

  • Lowry F. Chronic Migraine Responds to OnabotulinumtoxinA. Medscape Medical News. Available at http://www.medscape.com/viewarticle/825002. Accessed: May 19, 2014.

  • Minson CT, Green DJ. Measures of vascular reactivity: prognostic crystal ball or Pandora’s box?. J Appl Physiol. 2008 Aug. 105(2):398-9. [Medline].

  • [Guideline] Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24. 78(17):1337-45. [Medline]. [Full Text].

  • Source